XNCR
USDXencor Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$14.340
Kõrge
$14.340
Madal
$13.620
Maht
0.91M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
972.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.15M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Barclays Upgrades Xencor to Overweight, Raises Price Target to $23
Barclays analyst Etzer Darout upgrades Xencor from Underweight to Overweight and raises the price target from $6 to $23.
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $18
RBC Capital analyst Leonid Timashev maintains Xencor with a Outperform and raises the price target from $15 to $18.
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
Seotud aktsiad
UDMY
Udemy Inc.
CROX
Crocs Inc.
BTA
BlackRock Long-Term Municipal Advantage Trust Common Shares of Beneficial Interest
PHG
Koninklijke Philips N.V. NY Registry Shares
AGNC
AGNC Investment Corp.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.